Table 2.
Compound transgenic mouse AML models.
| Year | Co-Op Mutations | Activity | Promoter | Inducer | Cellular Target | Phenotype | Ref. |
|---|---|---|---|---|---|---|---|
| 2007 | NRAS12D + BCL2 | Const. | hMPP8 | Myeloid lineage (BM, periphery) | MDS/AML | [102] | |
| Cond. | Tet | rtTA | |||||
| 2012 | MLL-PTD + FLT3-ITD | Const. | Mll + Flt3 | Mll and Flt3 expressing cells | AML with 100% penetrance | [97] | |
| 2012 | NUP98-HOXD13 + FLT3-ITD | Conv. (FLT3-ITD) | Flt3 | Hematopoietic lineage cells (FL, BM) | AML with 100% penetrance | [98] | |
| Conv. (NUP98-HOXD12) | Vav | ||||||
| 2012 | KRAS-G12D + PML-RARA | Cond. (Kras-G12D) | Mx-iCre | Myeloid lineage (BM, periphery) | APL-like Disease with 69% penetrance, remaining mice developed MDS | [104] | |
| Const. (PML-RARA) | hCG | ||||||
| 2013 | NPM1c + FLT3-ITD | Cond. (NPM1c) | Mx1 | Mx-iCre | Hematopoietic lineage cells (BM) | AML after short latency (median 49 days) | [96] |
| Const. (Flt3-ITD) | |||||||
| 2014 | NRAS-G12D + CBFβ-SMMHC | Cond. | Mx1 | Mx-iCre | Hematopoietic lineage cells (BM) | AML after short latency (median 13.7 weeks) and full penetrance | [103] |
| 2017 | NPM1c + NRAS-G12D | Cond. | Mx1 | Mx.iCre | Hematopoietic lineage cells (BM) | AML with 95% penetrance, some mice develop MPN | [46] |
| NPM1c + FLT3-ITD | AML with 100% penetrance | ||||||
| 2018 | WT1-R394W + FLT3-ITD | Const. | Wt1 and Flt3 | Wt1 and Flt3 expressing cells | MPN-like disease or T-ALL after short latency-AML associated with LOH of Flt3 | [99] |
Const. (constitutive expression), Cond. (regulated expression), Conv. (conventional), FL (fetal liver), MPN (myeloproliferative neoplasms), T-ALL (T-cell acute lymphoblastic leukemia).